QIXBELZA Trademark

Trademark Overview


On Monday, September 28, 2020, a trademark application was filed for QIXBELZA with the United States Patent and Trademark Office. The USPTO has given the QIXBELZA trademark a serial number of 90217771. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The QIXBELZA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
qixbelza

General Information


Serial Number90217771
Word MarkQIXBELZA
Filing DateMonday, September 28, 2020
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 23, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, October 1, 2020NEW APPLICATION ENTERED
Monday, November 9, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 18, 2021ASSIGNED TO EXAMINER
Thursday, February 18, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 3, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 23, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 23, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 18, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, October 7, 2021SOU TEAS EXTENSION RECEIVED
Thursday, October 7, 2021SOU EXTENSION 1 FILED
Friday, October 15, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 15, 2021SOU EXTENSION 1 GRANTED
Saturday, October 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 31, 2022SOU TEAS EXTENSION RECEIVED
Thursday, March 31, 2022SOU EXTENSION 2 FILED
Thursday, March 31, 2022SOU EXTENSION 2 GRANTED
Saturday, April 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 12, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 12, 2022SOU EXTENSION 3 FILED
Wednesday, October 12, 2022SOU EXTENSION 3 GRANTED
Friday, October 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 19, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, April 19, 2023SOU EXTENSION 4 FILED
Wednesday, April 19, 2023SOU EXTENSION 4 GRANTED
Friday, April 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 17, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 17, 2023SOU EXTENSION 5 FILED
Friday, October 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Thursday, October 19, 2023SOU EXTENSION 5 GRANTED